SKLB083019

N/A

Report date: 2024/09/10 11:03:06

Base Information

Drug NameSKLB083019
Drug Alias NameSKLB083019SKLB-083019
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Galaxy Biopharma Co LtdSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Galaxy Biopharma Co LtdSichuan UniversityGalaxy Biomedical Investment Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A